glp 1 drugs and menopause GLP-1 Agonists in Perimenopause: Unique Risks Potential Opportunities Postmenopausal women on the GLP-1

The full concentration map for all seven sizes: *Any draw larger than 100 units (1.00 mL) exceeds a single U-100 barrel and must be split across multiple fills which is why the low-concentration 5 mg build becomes impractical at higher doses

Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis

Feb 2010;2(1):29-35

Contraindications and precautions Consider avoiding DSIP or consulting a physician if: Pregnant or breastfeeding (insufficient safety data) Taking naloxone or other opioid antagonists (may block effects) Using medications metabolized by peptidases (potential interactions) History of immune disorders (theoretical immunogenicity concern) Already using multiple sleep medications Drug interactions Because DSIP degrades via amino-peptidases in blood, medications affecting these enzymes (like the ACE inhibitor captopril) could theoretically alter DSIP metabolism